DAVID FRIEDLAND
Prescription History 1013988021
Internal Medicine - Hematology & Oncology in Pittsburgh, PA
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DAVID FRIEDLAND, an active Hematology & Oncology specialist practicing in Pittsburgh, PA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 68 documented patient claims. Among these therapy options, the most frequently utilized medication is Orgovyx, which accounts for 39 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other PA PrescribersVs. PA Avg |
|---|---|---|---|
| OrgovyxRelugolix | 39 | $2,660.42▼ below PA avg | ▼ Less than typical |
About Orgovyx: Relugolix is used to treat prostate cancer in men. Show more ▾ It is not a cure. Most types of prostate cancer need the hormone testosterone to grow and spread. Relugolix works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells. In 2024, this provider wrote 39 Medicare prescriptions for Orgovyx, about half the volume of the typical Pennsylvania prescriber of this medication (73). Medicare paid an average of $2,660.42 per fill, versus $2,703.07 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average PA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the PA average for this medication. 39 30-Day Fills standardized to 30-day supplies 1,168 Days of Medication total across all patients in 2024 | |||
| Abiraterone Acetate | 17 | $4,942.46 | ▼ Less than typical |
About Abiraterone Acetate: This medication is used to treat prostate cancer. Show more ▾ Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children. An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER. In 2024, this provider wrote 17 Medicare prescriptions for Abiraterone Acetate, about a third of the volume of the typical Pennsylvania prescriber of this medication (54.4). Medicare paid an average of $4,942.46 per fill, versus $2,288.77 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average PA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 17 30-Day Fills standardized to 30-day supplies 504 Days of Medication total across all patients in 2024 | |||
| AlunbrigBrigatinib | 12 | $20,090.95 | ≈ Typical |
About Alunbrig: Brigatinib is used to treat a certain type of lung cancer (non-small cell lung cancer). Show more ▾ It works by slowing or stopping the growth of cancer cells. An anaplastic lymphoma kinase inhibitor. In 2024, this provider wrote 12 Medicare prescriptions for Alunbrig, about the same volume as the typical Pennsylvania prescriber of this medication (12.6). Medicare paid an average of $20,090.95 per fill, versus $17,840.70 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average PA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for DAVID FRIEDLAND is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology & Oncology prescribing approach at this Pittsburgh, PA practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among PA prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
